Evolus Down Nearly 6%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Evolus Is Maintained at Overweight by Barclays
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Evolus Price Target Maintained With a $22.00/Share by Needham
Evolus Buy Rating Justified by Strong Market Positioning and Growth Projections
Express News | Evolus Inc : Mizuho Raises Target Price to $25 From $23
Barclays Maintains Evolus(EOLS.US) With Buy Rating, Raises Target Price to $20
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $23
Express News | Cantor Fitzgerald Reiterates Overweight on Evolus
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
Why Investors Shouldn't Be Surprised By Evolus, Inc.'s (NASDAQ:EOLS) 27% Share Price Surge
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (EOLS): Is It One of Caligan Partners' Top Holdings Now?
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Evolus (EOLS) and Humana (HUM)
Evolus, Inc. (NASDAQ:EOLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $16 to $27
Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Express News | Evolus Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Raised Its FY24 Revenue Guidance